| Symbol | EDSA |
|---|---|
| Name | EDESA BIOTECH, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 SPY COURT, MARKHAM, Ontario, L3R 5H6, Canada |
| Telephone | +1 905 475-1234 |
| Fax | — |
| — | |
| Website | https://www.edesabiotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001540159 |
| Description | Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The companys product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The companys EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients. Additional info from NASDAQ: |
Director Nijhawan Pardeep 🟢 acquired 1.2K shares of Edesa Biotech, Inc. (EDSA) Transaction Date: May 01, 2026 | Filing ID: 002942
Read moreDirector Nijhawan Pardeep 🟢 acquired 2.6K shares of Edesa Biotech, Inc. (EDSA) Transaction Date: Apr 01, 2026 | Filing ID: 002373
Read moreNew Form ARS - Edesa Biotech, Inc. <b>Filed:</b> 2026-04-03 <b>AccNo:</b> 0001171843-26-002238 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Edesa Biotech, Inc. <b>Filed:</b> 2026-04-03 <b>AccNo:</b> 0001171843-26-002237 <b>Size:</b> 742 KB
Read moreNew Form DEF 14A - Edesa Biotech, Inc. <b>Filed:</b> 2026-04-03 <b>AccNo:</b> 0001171843-26-002236 <b>Size:</b> 2 MB
Read moreNew Form SCHEDULE 13G - Edesa Biotech, Inc. <b>Filed:</b> 2026-03-16 <b>AccNo:</b> 0001193125-26-108289 <b>Size:</b> 359 KB
Read moreBrooks Michael J 🟢 acquired 2.0K shares of Edesa Biotech, Inc. (EDSA) at $1.57 Transaction Date: Feb 26, 2026 | Filing ID: 001490
Read moreDirector Nijhawan Pardeep 🟢 acquired 1.0K shares of Edesa Biotech, Inc. (EDSA) at $6.60 Transaction Date: Mar 10, 2026 | Filing ID: 001463
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06701656 | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Beva… | Phase2 | Acute Respiratory Distress Syndrome (ARDS) | Recruiting | 2025-10-28 | 2028-09-01 | ClinicalTrials.gov |
| NCT06701682 | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilo… | Phase2 | Acute Respiratory Distress Syndrome (ARDS) | Recruiting | 2025-06-21 | 2028-09-01 | ClinicalTrials.gov |
| NCT06701669 | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Pari… | Phase2 | Acute Respiratory Distress Syndrome (ARDS) | Recruiting | 2025-06-10 | 2028-09-01 | ClinicalTrials.gov |
| NCT06703073 | JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) | Phase2 | Acute Respiratory Distress Syndrome (ARDS) | Recruiting | 2025-06-10 | 2028-09-01 | ClinicalTrials.gov |
| NCT04401475 | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and… | Phase2 | COVID-19 | Suspended | 2020-11-25 | 2024-12-01 | ClinicalTrials.gov |
| NCT03680131 | Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatit… | Phase2 | Allergic Contact Dermatitis | Completed | 2019-10-15 | 2023-01-17 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Cohort C: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort C: bevacizumab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort B: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort B: paridiprubart | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort A: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort A: vilobelimab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort C: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701656 |
| Cohort C: bevacizumab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701656 |
| Cohort B: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701669 |
| Cohort B: paridiprubart | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701669 |
| Cohort A: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701682 |
| Cohort A: vilobelimab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701682 |
| Cohort C: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort C: bevacizumab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort B: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort B: paridiprubart | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort A: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort A: vilobelimab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort C: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701656 |
| Cohort C: bevacizumab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701656 |
| Cohort B: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701669 |
| Cohort B: paridiprubart | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701669 |
| Cohort A: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701682 |
| Cohort A: vilobelimab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701682 |
| Cohort C: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701656 |
| Cohort C: bevacizumab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701656 |
| Cohort B: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701669 |
| Cohort B: paridiprubart | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701669 |
| Cohort A: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701682 |
| Cohort A: vilobelimab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701682 |
| SOC plus Placebo IV | Other | Phase PHASE2 | COVID-19 | SUSPENDED | NCT04401475 |
| SOC plus 15mg/kg EB05 IV | Other | Phase PHASE2 | COVID-19 | SUSPENDED | NCT04401475 |
| EB01 Cream 2.0% | Other | Phase PHASE2 | Allergic Contact Dermatitis | COMPLETED | NCT03680131 |
| EB01 Cream 1.0% | Other | Phase PHASE2 | Allergic Contact Dermatitis | COMPLETED | NCT03680131 |
| EB01 Cream 0.2% | Other | Phase PHASE2 | Allergic Contact Dermatitis | COMPLETED | NCT03680131 |
| EB01 Cream Placebo | Other | Phase PHASE2 | Allergic Contact Dermatitis | COMPLETED | NCT03680131 |
| Cohort C: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort C: bevacizumab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort B: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort B: paridiprubart | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort A: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort A: vilobelimab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort A: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701682 |
| Cohort A: vilobelimab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701682 |
| Cohort B: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701669 |
| Cohort B: paridiprubart | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701669 |
| Cohort C: placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701656 |
| Cohort C: bevacizumab | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06701656 |
| Cohort A: placebo | DRUG | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort A: vilobelimab | DRUG | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort B: placebo | DRUG | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort B: paridiprubart | DRUG | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort C: placebo | DRUG | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| Cohort C: bevacizumab | DRUG | Phase PHASE2 | Acute Respiratory Distress Syndrome (ARDS) | RECRUITING | NCT06703073 |
| SOC plus Placebo IV | OTHER | Phase PHASE2 | COVID-19 | SUSPENDED | NCT04401475 |
| SOC plus 15mg/kg EB05 IV | BIOLOGICAL | Phase PHASE2 | COVID-19 | SUSPENDED | NCT04401475 |
| EB01 Cream 2.0% | DRUG | Phase PHASE2 | Allergic Contact Dermatitis | COMPLETED | NCT03680131 |
| EB01 Cream 1.0% | DRUG | Phase PHASE2 | Allergic Contact Dermatitis | COMPLETED | NCT03680131 |
| EB01 Cream 0.2% | DRUG | Phase PHASE2 | Allergic Contact Dermatitis | COMPLETED | NCT03680131 |
| EB01 Cream Placebo | DRUG | Phase PHASE2 | Allergic Contact Dermatitis | COMPLETED | NCT03680131 |